LeMaitre Vascular Inc. (NASDAQ:LMAT) was down 2.9% on Thursday . The stock traded as low as $13.79 and last traded at $13.83, with a volume of 74,273 shares traded. The stock had previously closed at $14.25.

Several equities research analysts have weighed in on LMAT shares. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Thursday, May 5th. Brean Capital reiterated a “buy” rating on shares of LeMaitre Vascular in a report on Tuesday, May 3rd. Canaccord Genuity reiterated a “buy” rating and issued a $18.00 price objective (up previously from $6.00) on shares of LeMaitre Vascular in a report on Tuesday, May 3rd. Finally, Roth Capital increased their price objective on LeMaitre Vascular from $18.00 to $18.50 and gave the stock a “buy” rating in a report on Tuesday, May 3rd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $17.61.

The company has a market capitalization of $257.86 million and a P/E ratio of 31.25. The firm’s 50-day moving average price is $14.36 and its 200-day moving average price is $14.81.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Monday, May 2nd. The company reported $0.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.01. On average, equities research analysts forecast that LeMaitre Vascular Inc. will post $0.48 earnings per share for the current year.

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 110,189 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $16.17, for a total transaction of $1,781,756.13. Following the sale, the chief executive officer now directly owns 3,549,133 shares of the company’s stock, valued at $57,389,480.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 1,740 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $15.49, for a total value of $26,952.60. Following the sale, the chief executive officer now directly owns 3,522,749 shares in the company, valued at $54,567,382.01. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have added to or reduced their stakes in the stock. GSA Capital Partners LLP boosted its position in LeMaitre Vascular by 12.6% in the fourth quarter. GSA Capital Partners LLP now owns 185,903 shares of the company’s stock worth $3,207,000 after buying an additional 20,785 shares in the last quarter. Russell Frank Co boosted its position in LeMaitre Vascular by 24.8% in the fourth quarter. Russell Frank Co now owns 113,832 shares of the company’s stock worth $1,992,000 after buying an additional 22,656 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in LeMaitre Vascular by 337.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 64,289 shares of the company’s stock worth $1,109,000 after buying an additional 49,589 shares in the last quarter. American Century Companies Inc. acquired a new position in LeMaitre Vascular during the fourth quarter worth approximately $1,209,000. Finally, Dimensional Fund Advisors LP boosted its position in LeMaitre Vascular by 8.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 866,308 shares of the company’s stock worth $14,944,000 after buying an additional 70,118 shares in the last quarter.

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.